Sunshine Biopharma Inc. Increase (Decrease) in Income Taxes Payable
Sunshine Biopharma Inc. (SBFM) reported Increase (Decrease) in Income Taxes Payable of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable · last filed 2026-08-13
- Sunshine Biopharma Inc. increase (decrease) in income taxes payable for the quarter ending 2026-06-30 was -$175.00, a 100.58% decline year-over-year.
- Sunshine Biopharma Inc. increase (decrease) in income taxes payable for the quarter ending 2026-03-31 was $175.00.
- Sunshine Biopharma Inc. increase (decrease) in income taxes payable for the quarter ending 2025-12-31 was -$152.87K.
- Sunshine Biopharma Inc. increase (decrease) in income taxes payable for the quarter ending 2025-09-30 was $162.99K, a 68.66% decline year-over-year.
- Sunshine Biopharma Inc. increase (decrease) in income taxes payable for fiscal 2025 was $0.00.
- Sunshine Biopharma Inc. increase (decrease) in income taxes payable for fiscal 2024 was -$812.08K.
- Sunshine Biopharma Inc. increase (decrease) in income taxes payable for fiscal 2023 was -$73.25K, a 130.69% decline from fiscal 2022.
- Sunshine Biopharma Inc. increase (decrease) in income taxes payable for fiscal 2022 was $238.68K.
| Period end | Increase (Decrease) in Income Taxes Payable 3 month | Increase (Decrease) in Income Taxes Payable 6 month | Increase (Decrease) in Income Taxes Payable 9 month | Increase (Decrease) in Income Taxes Payable 9 month as first filed | Increase (Decrease) in Income Taxes Payable 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$175.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | -$152.87K derived: sum of 3 quarters · filed 2026-08-13 | $10.12K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $175.00 10-Q · filed 2026-05-13 | -$152.70K derived: sum of 2 quarters · filed 2026-05-13 | $10.29K derived: sum of 3 quarters · filed 2026-05-13 | $40.34K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | -$152.87K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-03 | $10.12K derived: sum of 2 quarters · filed 2026-04-03 | $40.16K derived: sum of 3 quarters · filed 2026-08-13 | $0.00 10-K · filed 2026-04-03 | |
| 2025-09-30 | $162.99K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $193.03K derived: sum of 2 quarters · filed 2026-08-13 | $152.87K 10-Q · filed 2025-11-13 | $68.42K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $30.04K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$10.12K 10-Q · filed 2026-08-13 | -$94.57K derived: sum of 3 quarters · filed 2026-08-13 | $425.47K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | -$40.16K 10-Q · filed 2026-05-13 | -$124.61K derived: sum of 2 quarters · filed 2026-05-13 | $395.43K derived: sum of 3 quarters · filed 2026-05-13 | -$808.42K derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | -$84.45K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-03 | $435.59K derived: sum of 2 quarters · filed 2026-04-03 | -$768.26K derived: sum of 3 quarters · filed 2026-04-03 | -$812.08K 10-K · filed 2026-04-03 | |
| 2024-09-30 | $520.04K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$683.80K derived: sum of 2 quarters · filed 2025-11-13 | -$727.63K 10-Q · filed 2025-11-13 | $283.29K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | -$1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$1.25M 10-Q · filed 2025-08-12 | -$236.75K derived: sum of 3 quarters · filed 2025-08-12 | -$1.17M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$43.82K 10-Q · filed 2025-05-15 | $967.10K derived: sum of 2 quarters · filed 2025-05-15 | $30.91K derived: sum of 3 quarters · filed 2025-05-15 | -$159.92K derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $74.73K derived: sum of 2 quarters · filed 2025-04-01 | -$116.10K derived: sum of 3 quarters · filed 2025-04-01 | -$73.25K 10-K · filed 2025-04-01 | |
| 2023-09-30 | -$936.19K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2024-11-05 | -$1.13M derived: sum of 2 quarters · filed 2024-11-05 | -$1.08M 10-Q · filed 2024-11-05 | -$172.08K 10-Q · filed 2023-11-13 | -$845.49K derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$190.83K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2024-08-20 | -$147.98K 10-Q/A · filed 2024-08-20 | $90.70K derived: sum of 3 quarters · filed 2024-08-20 | $90.70K derived: sum of 4 quarters · filed 2024-08-20 | |
| 2023-03-31 | $42.85K 10-Q · filed 2024-05-20 | $281.53K derived: sum of 2 quarters · filed 2024-05-20 | $281.53K derived: sum of 3 quarters · filed 2024-05-20 | $281.53K derived: sum of 4 quarters · filed 2024-05-20 | |
| 2022-12-31 | $238.68K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $238.68K derived: sum of 2 quarters · filed 2024-03-28 | $238.68K derived: sum of 3 quarters · filed 2024-03-28 | $238.68K 10-K · filed 2024-03-28 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 | ||||
| 2021-12-31 | $0.00 10-K · filed 2023-04-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |